LONDON: Shield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company focused on iron deficiency, reported a sharp rise in revenues and prescription sales for the first half of 2025, as its flagship product ACCRUFeR® gained traction across key markets.
Group revenues surged to $21.4 million, up 1.8 times from $12.1 million in H1 2024, driven by robust U.S. sales of ACCRUFeR®, which contributed $19.2 million. Ex-U.S. revenues doubled to $2.2 million, reflecting milestone and royalty payments from partners in Europe, Canada, and Japan.
The company narrowed its net loss to $9.5 million from $15.5 million a year earlier, citing higher product revenues and streamlined expenditures. Cash and cash equivalents rose to $10.8 million, bolstered by a $10 million equity raise and partner payments, including $335,000 from Japan’s VITAL-NET and $552,000 from Europe’s Norgine BV.
ACCRUFeR® prescriptions in the U.S. climbed to approximately 84,000, up 1.3 times year-over-year, with average net selling price rising to $214 in H1 2025 from $158 in H1 2024. CEO Anders Lundstrom credited digital marketing and strategic access initiatives for the growth, noting strong uptake in six major states.
Internationally, Shield advanced its global footprint. ACCRUFeR® launched in Canada via Kye Pharmaceuticals, while ASK Pharma in China completed a Phase 3 study supporting a 2025 NDA filing. Regulatory submissions for pediatric use were made in both the EU and U.S., following positive trial results.
“We remain committed to driving sustained growth and establishing ACCRUFeR® as the preferred oral iron therapy,” Lundstrom said. “With strengthened cash reserves and expanding global partnerships, we are on track to become cash flow positive by year-end.”